Overview

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Phase:
Phase 1
Details
Lead Sponsor:
Merrimack Pharmaceuticals
Treatments:
Albumin-Bound Paclitaxel
Antibodies, Bispecific
Capecitabine
Cisplatin
Docetaxel
Lapatinib
Paclitaxel
Trastuzumab